Concepedia

Author

Stacy D. D’Andre

University of California, DavisORCID

Also Known As

S D’Andre, S. D'Andre, S. D’Andre, Stacy D. D’Andre, Stacy D'Andre, Stacy D. D'Andre, Stacy D. D’Andre, Stacy D. D’andre, Stacy DAndre, Stacy D’Andre

45

Publications

1.4K

Citations

11

H-Index

25

Concepts

All Affiliations

University of California, DavisMoffitt Cancer CenterMedical University of South CarolinaSutter Medical CenterDuke Medical Center
SD

About

Stacy D. D’Andre is an author at University of California, Davis specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

6

6

245

2

Health Sciences

2

2

97

3

Obstetrics

2

2

141

4

Cellular Physiology

1

1

10

5

Nephrology

1

1

10

Stacy D. D’Andre

×

11

Publications

1.3K

Citations

10

H-Index

YearCitations

First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma

Linda M. Liau, Keyoumars Ashkan, David D. Tran,

Journal of Translational Medicine

2018

528

Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma

Linda M. Liau, Keyoumars Ashkan, Steven Brem,

JAMA Oncology

2022

356

Effect of High Dose Vitamin C on Urinary Oxalate Levels

T. R. Wandzilak, Stacy D. D’Andre, Paul A. Davis,

The Journal of Urology

1994

110

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

Ignace Vergote, Giovanni Scambia, David M. O’Malley,

The Lancet Oncology

2019

85

Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With<i>ERBB2</i>Amplification or<i>ERBB2/3</i>Mutations: Results From the TAPUR Study

R. Gupta, Funda Meric‐Bernstam, Michael Rothe,

JCO Precision Oncology

2022

57

A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer.

Joyce F. Liu, Mark F. Brady, Ursula A. Matulonis,

Journal of Clinical Oncology

2020

56

5-Fluorouracil–Based Chemotherapy for Advanced Colorectal Cancer in Elderly Patients: A North Central Cancer Treatment Group Study

Stacy D. D’Andre, Daniel J. Sargent, S. Stephen,

Clinical Colorectal Cancer

2005

42

Pertuzumab plus trastuzumab (P+T) in patients (Pts) with colorectal cancer (CRC) with <i>ERBB2</i> amplification or overexpression: Results from the TAPUR Study.

R. Gupta, Elizabeth Garrett‐Mayer, Susan Halabi,

Journal of Clinical Oncology

2020

41

Topical Cannabinoids for Treating Chemotherapy-Induced Neuropathy: A Case Series

Stacy D. D’Andre, Sean D. McAllister, Jasdeepa Nagi,

Integrative Cancer Therapies

2021

24

A randomized phase II non-comparative study of Ispinesib given weekly or every three weeks in metastatic colorectal cancer. A California Cancer Consortium Study (CCC-P)

Anthony B. El-Khoueiry, Syma Iqbal, D. A. Singh,

Journal of Clinical Oncology

2006

11

Page 1